Journal of Commercial Biotechnology 2019-07-30T18:37:57+00:00 Art Boni Open Journal Systems <h2 style="margin: 0 0 .5em; font-weight: 300;">Leading thinking on biotechnology business management</h2> <p><img src="/public/site/images/dna2z/jcb_cover_small.jpg"></p> <p style="margin-top: 3px;">The <em>Journal of Commercial Biotechnology</em>, in print since 1994, is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with current issues and industry trends.</p> <p>Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:</p> <ul> <li class="show">Management</li> <li class="show">Policy</li> <li class="show">Finance</li> <li class="show">Law</li> <li class="show">Regulation</li> <li class="show">Bioethics</li> </ul> <p>The <em>Journal of Commercial Biotechnology</em> is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.</p> The 'Future of Food" is Genetic Engineering! 2019-07-30T18:37:57+00:00 Robert Wager 2019-02-06T17:02:28+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology Proposal for an innovating business model for supporting biotechnology companies, ecosystem and their founders 2019-07-30T18:37:38+00:00 Fabrice Heitzmann The pharmaceutical industry has been revolutionized by the new biotechnology companies during the last years. Facing patent expirations, lack of innovation and depleting product pipelines, the important structures turned to the funding of small biotechnology companies aimed at research and intellectual property securization. Alliances are primordial in the current economic climate. The market growth was questioned for years, but biotechnology companies shifted to product-driven strategies and the market performance has been verified during the last decade. Researchers still face challenges in transforming their science into businesses. They need to be fully equipped, and accompanied towards the right objectives to ensure the sustainability of the market as a whole. 2019-02-06T17:03:28+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology Financial investment risks in parmaceutical industry: analysis on fluctuation of stock price 2019-07-30T18:37:18+00:00 Wei Liang Hongxiang Ge <p><em>With the constant development of market economy, medical industry is developing rapidly, and many </em><em>listed pharmaceutical companies</em><em> have emerged. Stock price is an important standard for </em><em>measuring</em><em> the industrial development condition, and its influence factors are concerned by investors and issuing enterprises all the time. In this study, the factors affecting stock price were investigated taking the stock price of </em><em>listed pharmaceutical companies</em><em> in Shanghai in 2016 as the research samples and using correlation analysis and regression analysis. Variables such as </em><em>earnings per share</em><em>, drug price policies and </em><em>quick ratio</em><em> were introduced for correlation analysis. The research results suggested that the influence of earnings per share on stock price was the largest; the higher the earnings per share, the higher stock price; </em><em>interest rate</em><em> could also affect the fluctuation of stock price. This works aims to offer an evidence for investors who are subject to invest </em><em>listed pharmaceutical companies</em><em>.</em><em></em></p> 2019-02-06T17:04:57+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology Supervision and legal control of illegal marketing in medical and health care enterprises 2019-07-30T18:36:59+00:00 Qiong Sun Zhiyong Tan Zheng Liu Guanying Qin <p><em>Enterprise as </em><em>a for-</em><em>profit economic organization aim at profits anytime. Sale is an indispensable step in capital appreciation, and management at the level of transaction cycle is paid attention to. Under the background of the increasingly fierce competition in the pharmaceutical industry, a large number of problems have emerged in the circulation of medicine. Therefore, the </em><em>supervision </em><em>and legal control of illegal marketing</em><em>&nbsp;of</em><em>&nbsp;medi</em><em>cal</em><em>&nbsp;and health </em><em>care </em><em>enterprises has become the most important.</em><em>&nbsp;</em><em>In this paper, the problems of sales and </em><em>collection</em><em>&nbsp;in the illegal marketing of medi</em><em>cal</em><em>&nbsp;and health</em><em>&nbsp;care</em><em>&nbsp;enterprises </em><em>were </em><em>analyzed</em><em>, relevant laws were introduced, the improvement method for internal control of sales and collection cycle was put forward, and some suggestions were proposed for the transactions in the process of marketing of medical and health care products. This work provides a reference for the standardization of marketing means of medical and </em><em>health</em><em>&nbsp;care enterprises.</em></p> 2019-02-06T17:05:55+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology Barriers of Knowledge in Biopharmaceutical Research and Development in Japan 2019-07-30T18:36:40+00:00 TAKAAKI OHARA Seigo Nasu <p><strong>The purpose of this research was to explore major barriers and issues in knowledge for biopharmaceutical research and development (R&amp;D) in Japan and discuss why Japan had lagged behind Western nations in the field of biopharmaceutical R&amp;D.</strong></p><p><strong>Cases of three therapeutic antibodies and one therapeutic protein originating and released in Japan were studied and the Web of Science Core Collection was used to analyze biopharmaceutical drugs of Japan and the US with various indexes. Analysis results suggested that establishment of a high-level clinical research network connected with global networks would lead to development of blockbusters. Many of Japanese pharmaceutical companies failed to establish such clinical research network and this is presumably one reason of the gap between Japan and Western nations.</strong></p><p><strong>On the other hand, acquisition and exchange of knowledge within and between organizations were also explored. The few successful Japanese companies acquired not only formal knowledge but also implicit knowledge for various R&amp;D phases from basic researches to applied researches from top pharmaceutical companies of Western nations, whereas most Japanese companies have not successfully acquired such knowledge. It was assumed that this has also contributed to the gap from Western counterparts.</strong></p> 2019-02-06T17:06:32+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology Biotechnology-driven business model archetypes: Sustainability, Innovation and Commercial Viability 2019-07-30T18:36:20+00:00 George Peppou <p><strong>Purpose</strong></p><p>In spite of enthusiasm for biotechnologies to enable sustainability and the development of innovative sustainable business models, limited research, tools and resources exist. Therefore, this research questions how the business model of sustainable biotechnology-driven firms differs from other businesses.</p><p><strong>Methodology </strong></p><p>This article applies a structured content analysis method to enumerate sustainable business model archetypes in biotechnology firms focuses utilising secondary data from 64 existing. The triple-layer business model canvas is used as the categorisation matrix.</p><p><strong>Findings</strong></p><p>Five sustainable business model archetypes were identified for biotechnology firms. Findings highlight that sustainable biotechnology-driven businesses can reach a sustainable business model through either operating as an environmentally-led or economically-led domain.</p><p><strong>Research limitations/implications</strong></p><p>This article recognises that transitioning to a sustainable business model requires significant change to many facets of the business, therefore this study provides a template for future organisations, supporting the realisation of future, sustainable, biotechnology innovations.<strong><em></em></strong></p><p><strong>Originality/value </strong></p><p>Unlike previous studies this article focuses exclusively on biotechnology firms, as well as utilising the Triple Layer Business Model Canvas as the categorisation matrix, the first article to do so. This article provides a template for large-scale industrial businesses to build, or transition to, more sustainable business models utilising biotechnology. </p> 2019-02-06T17:07:14+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology Regulation and Market Influences on Innovation in Biotechnology 2019-07-30T18:36:01+00:00 Claudine Kearney <p>In today’s competitive landscape innovation in biotechology is a necessity as there is a continuous increase in chronic diseases globally such as cancer, cardiovascular diseases, diabetes and hepatitis B that is driving this demand. Biotechnology is one of the fastest growing industries with a growing demand for precision medicine and biosimilars, with bioinformatics expected to experience exponential growth in the coming years as a result of substantial innovation in the field. Innovation gives biotechnology companies the opportunity to grow faster and more competitive and ultimately influence the direction of the industry by developing drugs, medicines and therapeutics as well as environmentally friendly chemicals, fuels and materials that address the growing needs of society. Despite the continuous need for innovation in biotechnology, companies are influenced by a number of issues, in the development and commercialization of their innovations. In this paper the focus is on regulation and market influences on innovation in biotechnology. First, the influence of regulation and governments on innovation in biotechnology is discussed. Second, examines the role of marketing on innovation in biotechnology. Third, the impact of market and patient analysis on innovation in biotechnology is examined and a framework is proposed. Following that final conclusions are drawn.&nbsp;</p> 2019-02-06T17:08:06+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology The Opportunities to Develop a Successful Entrepreneurship and Business Model in Biotechnology: An Overview 2019-07-30T18:35:40+00:00 Prachi Tyagi Rakesh Singh Sengar Alok Kumar <p><strong>Biotechnology is an incredible technology promising a better future worldwide and proved to be genera of great outcomes. Since its inception it has been projected to bring fantastic advances along with huge economic rewards</strong><strong>, in short it promises more for less. Involvement of molecular biology in biotechnology lead its way into the various aspects of science based industries. Pharmacogenomics, drug discovery and drug delivery are the emerging tools in health industry which can only be possible due to the onset of biotechnology. Worldwide, pharmaceutical companies pursued research in the medicines and diagnostics by implementing biotechnology. Biotechnology is a major tool for improving human life by improving agriculture, human health and environment. &nbsp;Developing countries tend to have growing needs but scarce resources, therefore, such claims naturally appeal to those in power. The practical applications of Biotechnology extend from widely separated fields, creative minds, these ideas need to be researched and developed. Extent of scope in the field offer opportunities for great industrial growth. A novel product as a result of intensive research often leads to a business model. Past has seen several industries established by scientists to make a difference through their product by understanding the need of people and market potential. Entrepreneurial potential in biotechnology is governed by factors like development of technology as an only solution for the problem or the better solution for the currently available technologies. Critical testing and regulatory agency approval must be received prior to commercial production and marketing. Although the field has immense opportunity but the level of uncertainty and failure is also high. So, an efficient and well organized strategy should be followed to develop and deliver a successful business model for biotechnology. The paper presents an illustration about the business potential in biotechnology from incubation of an idea and its transformation into a value aided product or technology through various demanding and formative steps like financing, human resource and marketing. </strong></p> 2019-02-06T17:09:32+00:00 Copyright (c) 2019 Journal of Commercial Biotechnology